Biolase, Inc.
BIOL
BIOL was delisted on the 18th of June, 2024.
16 hedge funds and large institutions have $336K invested in Biolase, Inc. in 2023 Q4 according to their latest regulatory filings, with 6 funds opening new positions, 5 increasing their positions, 1 reducing their positions, and 2 closing their positions.
400% more repeat investments, than reductions
Existing positions increased: 5 | Existing positions reduced: 1
200% more first-time investments, than exits
New positions opened: 6 | Existing positions closed: 2
68% more capital invested
Capital invested by funds: $199K → $336K (+$136K)
33% more funds holding
Funds holding: 12 → 16 (+4)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AFM
Anson Funds Management
Dallas,
Texas
|
+$191K |
| 2 |
KWA
Kellett Wealth Advisors
Cincinnati,
Ohio
|
+$27.2K |
| 3 |
Citadel Advisors
Miami,
Florida
|
+$19.7K |
| 4 |
VF
Virtu Financial
New York
|
+$17.6K |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$15.6K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Walleye Capital
New York
|
-$31.5K |
| 2 |
Bank of America
Charlotte,
North Carolina
|
-$26 |
| 3 |
IA
IFP Advisors
Tampa,
Florida
|
-$6 |
BIOL Hedge Fund Activity: Q4 2023 in Review
16 of the 6,859 institutional investors tracked by Wall St. Rank reported a position in Biolase, Inc. (BIOL) for Q4 2023, worth a combined $336K — up 68% from $199K a quarter earlier.
Buyers outnumbered sellers: 6 funds opened new BIOL positions and 2 closed out — a net gain of 4 holders — while 5 added to existing stakes and 1 trimmed.
The largest buyer was Anson Funds Management, adding an estimated $191K. The largest seller was Walleye Capital, exiting entirely with an estimated $31.5K sold.
- 16 institutional investors held Biolase, Inc. (BIOL) as of Q4 2023, up from 12 in Q3 2023.
- Funds reported $336K of Biolase, Inc. stock for Q4 2023, up 68% quarter-over-quarter.
- 6 funds opened new Biolase, Inc. positions in Q4 2023 and 2 closed out, a net change of +4 holders.
- The largest Biolase, Inc. buyer in Q4 2023 was Anson Funds Management, an estimated $191K added.
- The largest Biolase, Inc. seller in Q4 2023 was Walleye Capital, an estimated $31.5K sold.
Based on aggregated 13F filings for Q4 2023.